Thr24
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr24  -  FOXO1A (human)

Site Information
LPRPRSCtWPLPRPE   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448560
Associated spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
immunoassay ( 14 ) , immunoprecipitation ( 15 , 20 ) , mass spectrometry ( 5 , 8 , 9 , 10 , 16 , 17 , 18 , 19 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 45 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 ) , mutation of modification site ( 4 , 20 , 56 , 57 , 59 , 60 , 61 , 63 , 67 , 68 , 69 ) , phospho-antibody ( 12 , 13 , 14 , 15 , 21 , 22 , 44 , 46 , 56 , 58 , 59 , 61 , 62 , 64 , 65 , 66 , 67 , 68 , 70 ) , western blotting ( 12 , 13 , 15 , 21 , 22 , 44 , 46 , 56 , 61 , 62 , 64 , 67 , 68 , 70 )
Disease tissue studied:
bone cancer ( 22 ) , Ewing's sarcoma ( 4 ) , brain cancer ( 22 ) , glioblastoma ( 22 ) , glioma ( 22 ) , breast cancer ( 22 , 56 ) , gastric cancer ( 23 , 49 , 50 ) , gastric carcinoma ( 23 , 49 , 50 ) , leukemia ( 18 , 19 ) , chronic myelogenous leukemia ( 18 , 19 ) , liver cancer ( 69 ) , lung cancer ( 22 , 23 , 44 , 47 , 48 , 52 , 53 , 56 ) , non-small cell lung cancer ( 47 , 48 , 52 , 53 , 56 ) , non-small cell lung adenocarcinoma ( 23 ) , non-small cell squamous cell lung carcinoma ( 23 , 47 , 48 ) , neuroblastoma ( 13 ) , soft tissue cancer ( 4 )
Relevant cell line - cell type - tissue:
'neuron, cortical'-brain ( 59 ) , 'neuron, hippocampal'-brain ( 59 ) , 'stem, embryonic' ( 26 , 65 ) , 293 (epithelial) ( 8 , 9 , 10 , 15 , 22 , 57 , 61 , 63 , 65 , 67 , 68 , 70 ) , 3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout] ( 60 ) , A549 (pulmonary) ( 22 , 44 ) , A673 (muscle cell) ( 4 ) , adipocyte ( 57 ) , BT-474 (breast cell) ( 56 ) , COS (fibroblast) ( 20 ) , DLD1 (intestinal) ( 58 ) , erythroid ( 66 ) , HCD 57 (erythroid) ( 66 ) , HCT116 (intestinal) ( 58 ) , HEK293T (epithelial) ( 56 ) , HeLa (cervical) ( 12 , 21 , 24 , 25 , 27 ) , HepG2 (hepatic) ( 69 ) , Hs 578T (breast cell) ( 56 ) , HUVEC (endothelial) ( 62 ) , HUVEC (endothelial) [IRS1 (human)] ( 62 ) , Jurkat (T lymphocyte) ( 16 , 17 ) , K562 (erythroid) ( 18 , 19 ) , liver ( 5 ) , LNCaP (prostate cell) ( 60 ) , MCF-7 (breast cell) ( 22 , 56 ) , MDA-MB-231 (breast cell) ( 56 ) , MKN-45 (gastric) ( 23 , 39 , 40 , 41 , 42 , 43 , 45 , 49 , 50 , 54 , 55 ) , NCI-H157 (pulmonary) ( 56 ) , NCI-H1703 (squamous) ( 23 , 28 , 29 , 30 , 31 , 32 , 37 , 38 , 47 , 48 , 51 , 52 , 53 ) , NCI-H3255 (pulmonary) ( 23 , 33 , 34 , 35 , 36 ) , PC-12 (chromaffin) ( 59 ) , SH-SY5Y (neural crest) ( 13 ) , SK-N-MC (neural crest) ( 4 ) , SKBr3 (breast cell) ( 56 ) , synoviocyte-synovium ( 46 ) , T lymphocyte-blood ( 46 , 64 ) , U2OS (bone cell) ( 22 ) , U87MG (glial) ( 22 ) , ZR-75-1 (breast cell) ( 56 )

Upstream Regulation
Regulatory protein:
Akt1 (human) ( 56 , 70 ) , Akt2 (human) ( 56 ) , Akt3 (human) ( 56 ) , IRS1 (human) ( 62 ) , PDK1 (human) ( 67 , 70 ) , PHLPP (human) ( 56 ) , PHLPP2 (human) ( 56 ) , PINK1 (human) ( 13 )
Putative in vivo kinases:
Akt1 (human) ( 70 )
Kinases, in vitro:
Akt1 (human) ( 67 , 68 , 70 )
Treatments:
AG1478 ( 13 ) , Akt-I-1 ( 21 ) , Akt_inhibitor_VIII ( 13 ) , anti-CD3 ( 64 ) , AZD8055 ( 22 ) , BAR501 ( 3 ) , BDNF ( 59 ) , EGF ( 13 , 44 ) , Epo ( 66 ) , H2O2 ( 15 ) , HGF ( 11 ) , IGF-1 ( 59 , 65 , 67 , 68 , 70 ) , IL-2 ( 64 ) , imatinib ( 23 ) , insulin ( 15 , 57 , 62 ) , K252a ( 59 ) , LY294002 ( 21 , 59 , 64 ) , neurotrophin-3 ( 59 ) , neurotrophin-4 ( 59 ) , NGF ( 59 ) , PD98059 ( 59 , 70 ) , PI-103 ( 13 ) , rapamycin ( 70 ) , resveratrol ( 15 ) , SCF ( 66 ) , siRNA ( 56 ) , wortmannin ( 13 , 65 , 70 )

Downstream Regulation
Effects of modification on FOXO1A:
intracellular localization ( 11 , 15 , 57 , 59 , 61 , 63 , 68 ) , molecular association, regulation ( 11 , 61 , 68 ) , phosphorylation ( 68 )
Effects of modification on biological processes:
cell growth, induced ( 4 ) , transcription, altered ( 20 ) , transcription, inhibited ( 3 , 4 , 11 , 57 , 63 )
Induce interaction with:
14-3-3 beta (human) ( 61 ) , 14-3-3 gamma (human) ( 68 ) , 14-3-3 zeta (human) ( 68 )
Inhibit interaction with:
DNA ( 11 )

Disease / Diagnostics Relevance
Relevant diseases:
HNSCC ( 14 )

References 

1

Saline M, et al. (2019) AMPK and AKT protein kinases hierarchically phosphorylate the N-terminus of the FOXO1 transcription factor, modulating interactions with 14-3-3 proteins. J Biol Chem
31308176   Curated Info

2

Shin S, et al. (2019) ERK2 regulates epithelial-to-mesenchymal plasticity through DOCK10-dependent Rac1/FoxO1 activation. Proc Natl Acad Sci U S A 116, 2967-2976
30728292   Curated Info

3

Renga B, et al. (2015) Reversal of Endothelial Dysfunction by GPBAR1 Agonism in Portal Hypertension Involves a AKT/FOXOA1 Dependent Regulation of H2S Generation and Endothelin-1. PLoS One 10, e0141082
26539823   Curated Info

4

Niedan S, et al. (2014) Suppression of FOXO1 is responsible for a growth regulatory repressive transcriptional sub-signature of EWS-FLI1 in Ewing sarcoma. Oncogene 33, 3927-38
23995784   Curated Info

5

Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62
24275569   Curated Info

6

Masui K, et al. (2013) mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. Cell Metab 18, 726-39
24140020   Curated Info

7

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

8

Mulhern D (2011) CST Curation Set: 12835; Year: 2011; Biosample/Treatment: cell line, HEK 293/PP242; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

9

Mulhern D (2011) CST Curation Set: 12836; Year: 2011; Biosample/Treatment: cell line, HEK 293/WYE-354; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

10

Mulhern D (2011) CST Curation Set: 12837; Year: 2011; Biosample/Treatment: cell line, HEK 293/WYE-354; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

11

Fafalios A, et al. (2011) A hepatocyte growth factor receptor (Met)-insulin receptor hybrid governs hepatic glucose metabolism. Nat Med 17, 1577-84
22081023   Curated Info

12

Xie X, et al. (2011) IkappaB kinase epsilon and TANK-binding kinase 1 activate AKT by direct phosphorylation. Proc Natl Acad Sci U S A 108, 6474-9
21464307   Curated Info

13

Murata H, et al. (2011) A new cytosolic pathway from a Parkinson disease-associated kinase, BRPK/PINK1: activation of AKT via mTORC2. J Biol Chem 286, 7182-9
21177249   Curated Info

14

Frederick MJ, et al. (2011) Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples. Am J Pathol 178, 548-71
21281788   Curated Info

15

Qiang L, Banks AS, Accili D (2010) Uncoupling of acetylation from phosphorylation regulates FoxO1 function independent of its subcellular localization. J Biol Chem 285, 27396-401
20519497   Curated Info

16

Possemato A (2010) CST Curation Set: 10123; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

17

Possemato A (2010) CST Curation Set: 10125; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

18

Beausoleil S (2010) CST Curation Set: 10278; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

19

Beausoleil S (2010) CST Curation Set: 10280; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

20

Kim S, Kim Y, Lee J, Chung J (2010) Regulation of FOXO1 by TAK1-Nemo-like kinase pathway. J Biol Chem 285, 8122-9
20061393   Curated Info

21

Singh A, et al. (2010) Protein phosphatase 2A reactivates FOXO3a through a dynamic interplay with 14-3-3 and AKT. Mol Biol Cell 21, 1140-52
20110348   Curated Info

22

Chresta CM, et al. (2010) AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 70, 288-98
20028854   Curated Info

23

Moritz A, et al. (2010) Akt-RSK-S6 Kinase Signaling Networks Activated by Oncogenic Receptor Tyrosine Kinases. Sci Signal 3, ra64
20736484   Curated Info

24

Zhou J (2009) CST Curation Set: 7633; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

25

Zhou J (2009) CST Curation Set: 7638; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

26

Brill LM, et al. (2009) Phosphoproteomic analysis of human embryonic stem cells. Cell Stem Cell 5, 204-13
19664994   Curated Info

27

Zhou J (2009) CST Curation Set: 6365; Year: 2009; Biosample/Treatment: cell line, HeLa/EGF; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

28

Moritz A (2009) CST Curation Set: 5891; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/rapamycin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

29

Moritz A (2009) CST Curation Set: 5892; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/rapamycin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

30

Moritz A (2009) CST Curation Set: 5895; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/U 0126; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

31

Moritz A (2009) CST Curation Set: 5889; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/wortmannin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

32

Moritz A (2009) CST Curation Set: 5885; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/Gleevec; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

33

Moritz A (2008) CST Curation Set: 5661; Year: 2008; Biosample/Treatment: cell line, NCI-H3255/U 0126; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

34

Moritz A (2008) CST Curation Set: 5652; Year: 2008; Biosample/Treatment: cell line, NCI-H3255/rapamycin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

35

Moritz A (2008) CST Curation Set: 5655; Year: 2008; Biosample/Treatment: cell line, NCI-H3255/Iressa; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

36

Moritz A (2008) CST Curation Set: 5658; Year: 2008; Biosample/Treatment: cell line, NCI-H3255/wortmannin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

37

Moritz A (2008) CST Curation Set: 5445; Year: 2008; Biosample/Treatment: cell line, NCI-H1703/U 0126; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

38

Moritz A (2008) CST Curation Set: 5448; Year: 2008; Biosample/Treatment: cell line, NCI-H1703/wortmannin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

39

Moritz A (2008) CST Curation Set: 5377; Year: 2008; Biosample/Treatment: cell line, MKN-45/U 0126; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

40

Moritz A (2008) CST Curation Set: 5378; Year: 2008; Biosample/Treatment: cell line, MKN-45/U 0126; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

41

Moritz A (2008) CST Curation Set: 5381; Year: 2008; Biosample/Treatment: cell line, MKN-45/wortmannin; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

42

Moritz A (2008) CST Curation Set: 5383; Year: 2008; Biosample/Treatment: cell line, MKN-45/rapamycin; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

43

Moritz A (2008) CST Curation Set: 5384; Year: 2008; Biosample/Treatment: cell line, MKN-45/rapamycin; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

44

VanMeter AJ, et al. (2008) Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type. Mol Cell Proteomics 7, 1902-24
18687633   Curated Info

45

Moritz A (2008) CST Curation Set: 5012; Year: 2008; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

46

Singh K, et al. (2008) Synoviocyte stimulation by the LFA-1-intercellular adhesion molecule-2-Ezrin-Akt pathway in rheumatoid arthritis. J Immunol 180, 1971-8
18209096   Curated Info

47

Moritz A (2007) CST Curation Set: 2952; Year: 2007; Biosample/Treatment: cell line, NCI-H1703/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

48

Moritz A (2007) CST Curation Set: 2953; Year: 2007; Biosample/Treatment: cell line, NCI-H1703/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

49

Moritz A (2007) CST Curation Set: 2964; Year: 2007; Biosample/Treatment: cell line, MKN-45/-; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

50

Moritz A (2007) CST Curation Set: 2965; Year: 2007; Biosample/Treatment: cell line, MKN-45/-; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

51

Moritz A (2007) CST Curation Set: 2945; Year: 2007; Biosample/Treatment: cell line, NCI-H1703/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (60D12F4) Rabbit mAb Cat#: 10002
Curated Info

52

Moritz A (2007) CST Curation Set: 2738; Year: 2007; Biosample/Treatment: cell line, NCI-H1703/Gleevec; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

53

Moritz A (2007) CST Curation Set: 2739; Year: 2007; Biosample/Treatment: cell line, NCI-H1703/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

54

Guo A (2007) CST Curation Set: 2749; Year: 2007; Biosample/Treatment: cell line, MKN-45/-; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

55

Guo A (2007) CST Curation Set: 2753; Year: 2007; Biosample/Treatment: cell line, MKN-45/-; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

56

Brognard J, Sierecki E, Gao T, Newton AC (2007) PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol Cell 25, 917-31
17386267   Curated Info

57

Armoni M, et al. (2006) FOXO1 represses peroxisome proliferator-activated receptor-gamma1 and -gamma2 gene promoters in primary adipocytes. A novel paradigm to increase insulin sensitivity. J Biol Chem 281, 19881-91
16670091   Curated Info

58

Samuels Y, et al. (2005) Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7, 561-73
15950905   Curated Info

59

Gan L, et al. (2005) Nuclear/cytoplasmic shuttling of the transcription factor FoxO1 is regulated by neurotrophic factors. J Neurochem 93, 1209-19
15934941   Curated Info

60

Huang H, et al. (2005) Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc Natl Acad Sci U S A 102, 1649-54
15668399   Curated Info

61

Zhao X, et al. (2004) Multiple elements regulate nuclear/cytoplasmic shuttling of FOXO1: characterization of phosphorylation- and 14-3-3-dependent and -independent mechanisms. Biochem J 378, 839-49
14664696   Curated Info

62

Federici M, et al. (2004) G972R IRS-1 variant impairs insulin regulation of endothelial nitric oxide synthase in cultured human endothelial cells. Circulation 109, 399-405
14707024   Curated Info

63

Zhang X, et al. (2002) Phosphorylation of serine 256 suppresses transactivation by FKHR (FOXO1) by multiple mechanisms. Direct and indirect effects on nuclear/cytoplasmic shuttling and DNA binding. J Biol Chem 277, 45276-84
12228231   Curated Info

64

Stahl M, et al. (2002) The forkhead transcription factor FoxO regulates transcription of p27Kip1 and Bim in response to IL-2. J Immunol 168, 5024-31
11994454   Curated Info

65

Rena G, et al. (2002) Two novel phosphorylation sites on FKHR that are critical for its nuclear exclusion. EMBO J 21, 2263-71
11980723   Curated Info

66

Mahmud DL, et al. (2002) Phosphorylation of forkhead transcription factors by erythropoietin and stem cell factor prevents acetylation and their interaction with coactivator p300 in erythroid progenitor cells. Oncogene 21, 1556-62
11896584   Curated Info

67

Woods YL, et al. (2001) The kinase DYRK1A phosphorylates the transcription factor FKHR at Ser329 in vitro, a novel in vivo phosphorylation site. Biochem J 355, 597-607
11311120   Curated Info

68

Rena G, et al. (2001) Roles of the forkhead in rhabdomyosarcoma (FKHR) phosphorylation sites in regulating 14-3-3 binding, transactivation and nuclear targetting. Biochem J 354, 605-12
11237865   Curated Info

69

Guo S, et al. (1999) Phosphorylation of serine 256 by protein kinase B disrupts transactivation by FKHR and mediates effects of insulin on insulin-like growth factor-binding protein-1 promoter activity through a conserved insulin response sequence. J Biol Chem 274, 17184-92
10358076   Curated Info

70

Rena G, et al. (1999) Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B. J Biol Chem 274, 17179-83
10358075   Curated Info